- Home
- RCEL vs COYA Comparison
RCEL vs COYA Comparison
Compare RCEL & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- COYA
- Stock Information
- Founded
- RCEL N/A
- COYA 2020
- Country
- RCEL United States
- COYA United States
- Employees
- RCEL N/A
- COYA N/A
- Industry
- RCEL Medical/Dental Instruments
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- RCEL Health Care
- COYA Health Care
- Exchange
- RCEL Nasdaq
- COYA Nasdaq
- Market Cap
- RCEL 113.7M
- COYA 107.0M
- IPO Year
- RCEL N/A
- COYA 2022
- Fundamental
- Price
- RCEL $4.56
- COYA $6.05
- Analyst Decision
- RCEL Strong Buy
- COYA Strong Buy
- Analyst Count
- RCEL 4
- COYA 4
- Target Price
- RCEL $13.75
- COYA $16.50
- AVG Volume (30 Days)
- RCEL 282.4K
- COYA 99.1K
- Earning Date
- RCEL 11-06-2025
- COYA 11-05-2025
- Dividend Yield
- RCEL N/A
- COYA N/A
- EPS Growth
- RCEL N/A
- COYA N/A
- EPS
- RCEL N/A
- COYA N/A
- Revenue
- RCEL $74,884,000.00
- COYA $423,452.00
- Revenue This Year
- RCEL $28.23
- COYA N/A
- Revenue Next Year
- RCEL $35.24
- COYA N/A
- P/E Ratio
- RCEL N/A
- COYA N/A
- Revenue Growth
- RCEL 38.32
- COYA N/A
- 52 Week Low
- RCEL $3.60
- COYA $4.65
- 52 Week High
- RCEL $14.16
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- RCEL 46.58
- COYA 43.93
- Support Level
- RCEL $4.12
- COYA $6.05
- Resistance Level
- RCEL $4.44
- COYA $6.53
- Average True Range (ATR)
- RCEL 0.25
- COYA 0.48
- MACD
- RCEL 0.03
- COYA -0.06
- Stochastic Oscillator
- RCEL 50.00
- COYA 17.31
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.